

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)



(10) International Publication Number
WO 2023/164769 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) *C07B 59/00* (2006.01)
A61K 47/22 (2006.01) *C07K 1/13* (2006.01)
A61P 35/00 (2006.01) *C07K 7/06* (2006.01)

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/CA2023/050269

(22) International Filing Date:

02 March 2023 (02.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/315,974 02 March 2022 (02.03.2022) US
63/316,381 03 March 2022 (03.03.2022) US

(71) Applicant: **POINT BIOPHARMA, INC.** [CA/CA]; 22 St.
Clair Avenue East, Suite 1201, Toronto, Ontario M4T 2S3
(CA).

(72) Inventors: **MCCANN, Joe**; c/o Point Biopharma, Inc., 22
St. Clair Avenue East, Suite 1201, Toronto, Ontario M4T
2S3 (CA). **DOMAN, Mark**; c/o Point Biopharma, Inc., 22
St. Clair Avenue East, Suite 1201, Toronto, Ontario M4T
2S3 (CA).

(74) Agent: **SCHROEDER, Hans** et al.; GOWLING WLG
(CANADA) LLP, Suite 2600, 160 Elgin Street, Ottawa, On-
tario K1P 1C3 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: **RADIOPHARMACEUTICAL AND METHODS**

(57) Abstract: A radiopharmaceutical ¹⁷⁷Lu-DOTATATE compound, a composition comprising one or more ascorbate compounds with the substantial or complete absence of a gentisate compound, a single or multiple dosage kit, and a sealed container are provided. Further provided are methods of synthesis of a ¹⁷⁷Lu-DOTATATE compound, and methods of treating a patient suffering from cancer specifically neuroendocrine tumors.



WO 2023/164769 A1